

SEQUENCE LISTING

<110> AUSTEN, MATTHIAS
BURK, ULRIKE

<120> METHOD FOR PREVENTING AND TREATING DIABETES USING NEURTURIN

<130> WEICKM-0058

<140> 10/580,601

<141> 2006-05-25

<150> PCT/EP04/13534

<151> 2004-11-29

<150> EP 03027383.3

<151> 2003-11-27

<160> 8

<170> PatentIn version 3.5

<210> 1

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
mDG770 transgene specific forward primer

<400> 1

tgctatctgt ctggatgtgc c

21

<210> 2

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
mDG770 transgene specific reverse primer

<400> 2

aaggacacct cgtcctcata g

21

<210> 3

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
mDG770-1 forward primer

<400> 3
gcctatgagg acgaggtgtc c 21

<210> 4
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
mDG770 reverse primer

<400> 4
agctcttgca gcgtgtggt 19

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
mDG770 probe

<400> 5
tcctggacgt gcacagccgc 20

<210> 6
<211> 594
<212> DNA
<213> Homo sapiens

<400> 6
atgcagcgct ggaaggcggc ggccttggcc tcagtgtctt gcagctccgt gctgtccatc 60
tggatgtgtc gagagggcct gcttctcagc caccgcctcg gaectgcgtt ggtccccctg 120
caccgcctgc ctgcaaccct ggacgcccgg attgcccgcc tggcccagta ccgtgcactc 180
ctgcaggggg ccccggtatgc gatggagctg cgcgagctga cgcctggggc tggcgggccc 240
ccaggctccgc gccgtcgggc ggggccccgc cggcggcgcg cgcgtgcgcg gttgggggcg 300
cggccttcgc ggctgcgcga gctggaggtg cgcgtgagcg agctgggcct gggctacgcg 360
tccgacgaga cgggtgtgtt ccgtactatc gcaggcgcct gcgaggtgcg cgcgcgcgtc 420
tacgacctcg ggctgcgcag actgcgcag cggcggcgcg tgcggcgagg gcgggtgcgc 480
gcgcagccct gctgccgcc gacggcctac gaggacgagg tgtccttctt ggacgcgcac 540
agccgctacc acacgggtgca cgagctgtcg gcgcgcgagt gcgcctgcgt gtga 594

<210> 7
<211> 197
<212> PRT
<213> Homo sapiens

<400> 7
Met Gln Arg Trp Lys Ala Ala Ala Leu Ala Ser Val Leu Cys Ser Ser
1 5 10 15

Val Leu Ser Ile Trp Met Cys Arg Glu Gly Leu Leu Leu Ser His Arg
20 25 30

Leu Gly Pro Ala Leu Val Pro Leu His Arg Leu Pro Arg Thr Leu Asp
35 40 45

Ala Arg Ile Ala Arg Leu Ala Gln Tyr Arg Ala Leu Leu Gln Gly Ala
50 55 60

Pro Asp Ala Met Glu Leu Arg Glu Leu Thr Pro Trp Ala Gly Arg Pro
65 70 75 80

Pro Gly Pro Arg Arg Arg Ala Gly Pro Arg Arg Arg Arg Ala Arg Ala
85 90 95

Arg Leu Gly Ala Arg Pro Cys Gly Leu Arg Glu Leu Glu Val Arg Val
100 105 110

Ser Glu Leu Gly Leu Gly Tyr Ala Ser Asp Glu Thr Val Leu Phe Arg
115 120 125

Tyr Cys Ala Gly Ala Cys Glu Ala Ala Ala Arg Val Tyr Asp Leu Gly
130 135 140

Leu Arg Arg Leu Arg Gln Arg Arg Arg Leu Arg Arg Glu Arg Val Arg
145 150 155 160

Ala Gln Pro Cys Cys Arg Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe
165 170 175

Leu Asp Ala His Ser Arg Tyr His Thr Val His Glu Leu Ser Ala Arg
180 185 190

Glu Cys Ala Cys Val
195

<210> 8

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 8

tttttttttt tttttt